Novastan (Argatroban Monohydrate)

Argatroban binds reversibly to thrombin’s active site, directly blocking the conversion of fibrinogen to fibrin. This inhibition stops the final step of the clotting cascade, producing rapid and controllable anticoagulation without affecting upstream clotting factors.

The dosing regimen for Novastan is individualized and set by the prescribing clinician based on the patient’s clinical condition, weight, renal and hepatic function, and laboratory monitoring of anticoagulation parameters.

Safety data for Argatroban in pregnancy and lactation are limited. It should be used only if the potential maternal benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Compared with heparin, Argatroban does not bind plasma proteins and has a predictable anticoagulant effect, making it useful in heparin‑induced thrombocytopenia. Unlike some oral anticoagulants, it is administered intravenously and offers rapid onset and offset, which is advantageous during procedures requiring tight anticoagulation control.

Novastan should be stored at 2‑8 °C, protected from light, and kept in its original packaging. It must not be frozen or shaken vigorously. Before use, allow the product to reach room temperature if required by the manufacturer’s reconstitution instructions.

Novastan is given by intravenous infusion. The infusion rate and duration are determined by the prescriber and are adjusted according to laboratory monitoring of anticoagulation (e.g., activated clotting time or aPTT) to achieve the desired therapeutic range.

The most serious risks include severe or uncontrolled bleeding, anaphylactic reactions, hepatic dysfunction, and rare events such as disseminated intravascular coagulation. Patients should be closely monitored for signs of bleeding and liver enzyme changes during therapy.

Novastan is contraindicated in patients with known hypersensitivity to Argatroban or any component of the formulation, in those with active major bleeding, and in individuals for whom alternative anticoagulation strategies are more appropriate based on clinical judgment.